Bruns Ingmar bought ZNTL
January 8, 2026 · Form 4 insider transaction
Bruns Ingmar bought 365,000 shares of Zentalis Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
365,000
Price
$0.00
Total value
N/A
InsiderBruns Ingmar
Role—
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJanuary 8, 2026
Filing dateJanuary 9, 2026
Shares owned after365,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.